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INTRODUCTION 
 
 
Chronic Kidney Disease (CKD) encompasses a spectrum of different 
pathophysiologic processes associated with abnormal kidney function, and a 
progressive decline in glomerular filtration rate.1 The prevalence of CKD in 
India is 0.78% -0.8% 2. The  crude and age adjusted incidence rates of stage 5 
CKD or End Stage Renal Disease (ESRD) is 151 and 232 per million 
population repectively.3 Uremia is defined as a clinical syndrome associated 
with fluid, electrolyte, and hormone imbalances and metabolic abnormalities, 
which develop in parallel with deterioration of renal function. 
 Peripheral neuropathy is a severe, disabling complication of uremia. 
Uremic neuropathy is a distal sensorimotor polyneuropathy supposedly caused 
by uremic toxins. The severity of neuropathy is correlated strongly with the 
severity of the renal insufficiency. Uremic neuropathy is considered a dying-
back neuropathy or central-peripheral axonopathy associated with secondary 
demyelination. However, uremia and its treatment can also be associated with 
mononeuropathy at compression sites. 
Charcot suspected the existence of uremic neuropathy in 1880.4 Since the 
introduction of haemodialysis and renal transplantation in the early 1960s, 
uremic neuropathy has been investigated thoroughly. Asbury, Victor, and 
                                                                                                                                                   
   
 
Adams5 described the clinical and pathologic features of uremic peripheral 
neuropathy in detail in 1962. 
In 1971, Dyck and colleagues6 established the current concept of uremic 
neuropathy based on their extensive nerve conduction studies in vivo and in 
vitro and on light and electron microscopy studies. Using quantitative histology, 
they demonstrated axonal shrinkage. Myelin sheaths appeared to be affected out 
of proportion to axons. The dysfunction of the neuron, rather than the Schwann 
cell, resulted in a decrease in the diameter of the axon, rearrangement of 
myelin, and finally, complete degeneration of the axon. 
   The peripheral neuropathies have been variably described by the 
patients as paraesthesias, pain, weakness and atrophy of lower limbs, muscle 
cramps, restless legs and sometimes presents like Guillain-Barre like features. 
Various modalities of renal replacement have restored the peripheral nerve 
functions or sometimes halt its progression. The rate of reversibility depends on 
various parameters such as duration symptoms, modality of renal replacement, 
adequacy of dialysis and so on. Of all the modalities, a matched renal transplant 
offers the best results for the improvement of symptoms. 
This study is targeted to highlight the presence and various attributes of 
clinical as well as subclinical peripheral neuropathy in patients who are 
undergoing intermittent peritoneal dialysis programme in our hospital. 
                                                                                                                                                   
   
 
AIMS AND OBJECTIVES 
 
 
 
The present project was undertaken to study  
 
1. The clinical and electrophysiological features of peripheral neuropathy in 
patients with chronic renal failure. 
 
2. Variations in clinical and electrophysiological features of peripheral 
neuropathy during the course Intermittent Peritoneal Dialysis. 
 
3. The correlation of various serological, hematological parameters to that 
of uremic peripheral neuropathy. 
 
 
 
 
 
 
 
                                                                                                                                                   
   
 
REVIEW OF LITERATURE 
 
1) Incidence: 
Peripheral neuropathy in patients with renal failure has been recognized 
for over 100 years. This disorder, however, was not fully appreciated until the 
early 1960s. Prior to the institution of chronic dialysis therapy, majority of 
patients with end-stage renal disease probably did not live long enough to 
develop clinically apparent neuropathy. Peripheral neuropathy occurs in upto 
65% of patients prior to or shortly after starting upon dialysis for CRF 7. 
According to Nielsen, of 109 patients in Denmark with chronic renal failure, 
77% reported clinical symptoms, and 51% had clinical signs of a neuropathy.8  
Bolton and Young claimed the incidence of clinical uremic neuropathy to be 
10-83% in patients with renal failure.9 Males develop peripheral neuropathy 
several times frequently than females. The basis of this interesting observation 
remains unexplained. Nielsen reported the male-to-female ratio as 60:49 in his 
109 patients.8 Individual serologic and biochemical abnormalities (calcium, 
magnesium, phosphate, urea, creatinine etc) do not correlate well with the 
incidence of neuropathy. The chronicity and severity of renal failure appear to 
be more important to the development of neuropathy. 7, 8, 10 No reported study 
has examined the role of race in uremic neuropathy. Uremic polyneuropathy 
                                                                                                                                                   
   
 
may occur at any age once the degree of renal failure is sufficient. Apart from 
the various aspects of peripheral neuropathy, uremia causes various autonomic 
as well as central nervous system manifestations. 
 
2) Etiology of uremic peripheral neuropathy: 
Although, the metabolic derangements responsible for uremic neuropathy 
have not been identified, a number of observations have been made with regard 
to potential urotoxins that might lead to the uremic neuropathy. These include 
guanidine compounds, parathyroid hormone, middle molecules, myoinositol 
and so on. Although any or all of these agents may play a role in the 
development of uremic neuropathy, the actual evidence that they are bonafide 
neurotoxins is scant. 
Numerous studies have been carried out in order to identify which of the 
many compounds that are elevated in uremic subjects is truly a uremic toxin. In 
the early days of dialysis, so-called “middle molecules” were said to be likely 
candidates as uremic toxins.11 Although evidence was mainly observational, the 
concept lasted a long time.12 The observation that uremic neuropathy improves 
with dialysis has led most observers to conclude that neuropathy results from 
accumulation of a dialyzable metabolite. Schribner has speculated that these 
substances might be in the middle molecule range (compounds with molecular 
                                                                                                                                                   
   
 
weights of 500-2,500 Da); compounds of this size cross most dialysis 
membranes much more slowly than smaller molecules like creatinine and urea, 
which are the usual measure of biochemical control of uremia.10 Thus, one 
might theoretically achieve chemical control of uremia, while failing to remove 
the offending toxins of the middle-molecular range. Observations supporting 
this point of view have been (1) that control of neuropathy may, depend on 
increased hours of dialysis per week, beyond that which is necessary for the 
control of uremia and (2)that peritoneal dialysis appears to be associated with a  
lower incidence of neuropathy, inspite of persisting high levels of urea and 
creatinine, suggesting that peritoneal membrane passes toxic molecules more 
readily and selectively than cellophane membranes used in haemodialysis 
machines.10 In one study by Raskin et al however, which included 5 uremic 
patients with neuropathy and 25 without neuropathy, the correlation between a 
calculated middle molecule concentration and the presence of neuropathy was 
poor.10 Also, maneuvers that might be expected to  increase the removal of 
middle molecule have had little demonstrable effect in peripheral nerve 
function. The ‘middle-molecule’ hypothesis is thus attractive, but there is as yet 
little rigorous evidence to support it.  
A decade later, criteria were established by Bergstom and Furst for 
uremic toxins. The criteria are as follows13 (1) the compound should be 
                                                                                                                                                   
   
 
chemically identified and quantifiable in biologic fluids, (2) the concentration 
of the substance in plasma from uremic subjects should be higher than that 
found in subjects who do not have renal insufficiency, (3) the concentration of 
the substance in plasma should somehow correlate with specific uremic 
symptoms, and these should be alleviated with reduction of the substance to 
normal, (4) the toxic effects of the substance should be demonstrable at 
concentrations found in plasma from uremic patients. 
Uremic neurotoxins would imply retention of solutes that have specific 
detrimental effects upon nervous system function, whether peripheral nervous 
system or central nervous system. 14, 15
There are at least three different types of uremic solutes that are 
potentially toxic and that can be characterized.16 These include (1) small water 
soluble compounds14 (2) middle molecules, (3) protein-bound compounds. Most 
of the small water soluble compounds, such as urea and creatinine, are not 
particularly toxic and are easily removed with dialysis. A low molecular weight 
compound for which there is increasing evidence for a role in the pathogenesis 
of stroke, atherosclerosis, and cardiovascular disease is asymmetric 
dimethylarginine (ADMA). 17, 18 
Presently no single uremic toxin has been shown to affect peripheral nerve 
function. Most of the evidence suggests that uremic neuropathy may be related 
                                                                                                                                                   
   
 
to anatomical nerve damage and also to cumulative effects of multiple toxic 
agents.19, 20 Possible uremic toxins are listed here, but most remain unproven. 
• Small water-soluble compounds 
o Guanidines 
o Asymmetric dimethylarginine 
o Creatinine 
o Purines 
o Oxalate 
o Phosphorus 
o Urea 
• Middle, large molecules 
o Advanced glycosylated end products 
o Parathyroid hormone 
o Oxidation products 
o Peptides (beta-endorphin, methionine-enkephalin, beta-lipotropin, 
granulocyte inhibiting proteins I and II, degranulation-inhibiting 
protein, adrenomedullin) 
o Beta 2-microglobulin 
o Complement factor D 
 
                                                                                                                                                   
   
 
• Protein-bound compounds 
o Indoles 
o 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid 
o Hippuric acid 
o Homocysteine 
o Indoxyl sulfate 
o P-cresol 
o Polyamines 
 
Guanidine Compounds  
Guanidine compounds have been postulated to be “uremic toxins” for 
many years, 21 based on possible detrimental effects on the central nervous 
system. Recent studies have demonstrated that several guanidino compounds 
are present in uremic brain 22 and may be important in the etiology of uremic 
encephalopathy.23 There are at least four guanidino compounds that are 
experimental convulsants. These guanidino compounds appear to work by 
activation of N-methyl-D-aspartate (NMDA) receptors by guanidino-succinic 
acid (GSA). Activation of the NMDA receptor is a major pathologic 
mechanism in the etiology of several types of brain damage, including head 
trauma 24 and stroke. 25, 26
                                                                                                                                                   
   
 
In addition, guanidine compounds have a depressant effect on 
mitochondrial function.27 In brain of uremic patients, guanidino compounds 
were measured in 28 different regions.28 Guanidinosuccinic acid levels were 
elevated by up to 100-fold in uremic brain versus control brain, and levels 
increased with increasing extent of uremia. The brain levels of 
guanidinosuccinic acid in uremic brain were similar to those observed in normal 
animal brain following injection to blood levels, which cause convulsions.28  
Guanidines inhibit neutrophil superoxide production, can induce seizures, 
and suppress natural killer cell response to interleukin-2.29 Other guanidines, 
which are arginine analogues, are competitive inhibitors of nitric oxide (NO) 
synthetase, which impairs removal of AGEs30 and can lead to vasoconstriction, 
hypertension, ischemic glomerular injury, immune dysfunction, and 
neurological changes.29 Two other low molecular weight compounds that have 
been recently studied appear to be important uremic toxins are diotyrosine-
containing cross-linked protein products (designated AOPPs) and asymmetric 
dimethylarginine (AMDA). 17, 18 The AOPPs behave as do mediators of 
inflammation and are found in very high concentration in the plasma of dialysis 
patients. ADMA is an inhibitor of nitric oxide and is associated with high 
plasma levels of homocysteine.18  
                                                                                                                                                   
   
 
With established renal insufficiency, guanidines, which are competitive 
inhibitors of nitric oxide (NO) synthetase, will rapidly accumulate in blood, and 
their presence will impair removal of AGEs30 and can lead to worsening 
hypertension, immune dysfunction,31 and neurological changes,32 such as 
stroke.33
Advanced Glycation End Products  
Advanced glycosylation (glycation) end products (AGEs) can modify 
tissues, enzymes, and proteins and may play a role in the pathogenesis of 
dialysis-associated amyloidosis.34 Advanced glycosylation end products may 
also play a role in the pathogenesis of diabetic nephropathy.35 Advanced 
glycosylation end products are markedly elevated in plasma of patients with 
ESRD.36 The AGEs react with vascular cells to inactivate endothelial nitric 
oxide and may increase the propensity of ESRD patients to develop 
hypertension. Current dialysis therapy is relatively ineffective in removal of 
AGEs, so that there is accumulation of AGEs in patients with ESRD, 
particularly those with diabetes mellitus. The AGEs are “middle molecules” and 
have the potential to cause tissue damage and lead to hypertension. Thus, at 
least some “middle molecules” may actually be deleterious in patients with 
ESRD, and they are poorly removed with conventional dialysis.36 There is 
evidence that angiotensin converting enzyme antagonists decrease the 
                                                                                                                                                   
   
 
formation of AGEs37 Protein-bound compounds (toxins) are not substantially 
removed by dialysis, and almost all are lipophilic. Such compounds include 
polyamines such as spermine.38 Spermine is postulated to be a uremic toxin and 
appears to react with the N-methyl-D-aspirate (NMDA) receptor, which affects 
calcium and sodium permeability in brain cells.38 Stimulation of the NMDA 
receptor in brain is the final common pathway for brain cell death in a number 
of pathological pathways. 39, 40 The uremic state is associated with increased 
oxidative stress, resulting in protein oxidation products in plasma and cell 
membranes. There is eventual alteration of proteins with formation of oxidized 
amino acids, including glutamine and glutamate.34 Such reactions may 
eventually lead to stimulation of the NMDA receptor in brain, with brain cell 
damage or death. 
Parathyroid Hormone  
In patients dying with acute or chronic renal failure, the calcium content 
in brain cerebral cortex is significantly elevated. 41, 42, 43  Dogs with acute or 
chronic renal failure show increases of brain gray matter calcium and have EEG 
changes similar to those seen in humans with acute renal failure. 44, 45 In dogs, 
both the EEG and brain calcium abnormalities can be prevented by 
parathyroidectomy. Conversely, these abnormalities can be reproduced by 
administration of parathyroid hormone to normal animals while maintaining 
                                                                                                                                                   
   
 
serum calcium and phosphate in the normal range. Thus, parathyroid hormone 
is essential to produce some of the central nervous system manifestations in the 
canine model of uremia. 43, 46 In addition, hyperparathyroidism in subjects with 
chronic renal failure is strongly associated with multiple types of cardiovascular 
disease, including myocardial infarction, congestive heart failure, 47 and 
stroke.48
Parathyroid hormone is known to have central nervous system effects in 
humans even in the absence of impaired renal function. Neuropsychiatric 
symptoms have been reported to be among the most common manifestations of 
primary hyperparathyroidism.49-52 Patients with primary hyperparathyroidism 
also have EEG changes similar to those observed in patients with acute renal 
failure. 41, 53 The common denominator appears to be elevated plasma levels of 
parathyroid hormone. 41, 45 In patients with acute renal failure the EEG is 
abnormal within 18 hours of the onset of renal failure and is generally not 
affected by dialysis for periods of up to 8 weeks.41 In patients with either 
primary or secondary hyperparathyroidism, parathyroidectomy results in an 
improvement of both EEG and psychological testing, suggesting a direct effect 
of parathyroid hormone on the central nervous system. Similarly, dialysis 
results in a decrement of brain (cerebral cortex) calcium toward normal in both 
patients and laboratory animals with renal failure concomitant with 
                                                                                                                                                   
   
 
improvement of the EEG. 41,42,43,45 In uremic patients, both EEG changes and 
psychological abnormalities are improved by parathyroidectomy or medical 
suppression of parathyroid hormone.42 Parathyroid hormone, a high brain 
calcium content, and abnormal calcium transport are probably responsible, at 
least in part, for some of the encephalopathic manifestations of renal failure. 
The mechanisms by which parathyroid hormone might impair central nervous 
system function are now better understood but far from complete. The increased 
calcium content in such diverse tissues as skin, cornea, blood vessels, brain, and 
heart in patients with hyperparathyroidism suggests that parathyroid hormone 
may somehow facilitate the entry of Ca2+ into such tissues.  
The finding of increased calcium in the brains of both dogs and humans 
with either acute or chronic renal disease and secondary hyperparathyroidism is 
consistent with the conception that part of the central nervous system 
dysfunction and EEG abnormalities found in acute renal failure or chronic renal 
failure may be due in part to a parathyroid hormone mediated increase in brain 
calcium. Calcium is essential for the function of neurotransmission in the 
central nervous system as well as a number of intracellular enzyme systems. 
Increased brain calcium content could disrupt cerebral function by interfering 
with either of these processes. 54,55 
 
                                                                                                                                                   
   
 
Transketolase 
. It has been suggested that transketolase, a thiamine dependent enzyme 
in the pentose phosphate pathway found in the erythrocytes and neural tissues, 
is inhibited by the accumulation of low molecular weight toxins in uremia, 
which might lead to subsequent neuropathy.10 It has been demonstrated that 
erythrocyte transketolase activity was frequently inhibited in pre-dialysis blood 
samples of patients on long term haemodialysis, but rose sharply in the post-
dialysis blood samples; but its relationship to neuropathy or uremia is yet to be 
settled. In addition, it is not known whether other important enzyme systems are 
equally or more affected by the accumulation of uremic toxins, nor is known 
whether transketolase plays a critical role in the maintenance of normal 
peripheral nerve function.56,57,58
Myoinositol  
Elevated plasma levels of myoinositol in patients with chronic renal 
failure have been suggested as a factor in the development of uremic 
neuropathy. Myoinositol is a water soluble, cyclic hexitol, with a molecular 
weight of 180 Daltons. It is a precursor of phosphoinositides, a class of 
phospholipids, whose rapid turnover in neural tissues has resulted in speculation 
linking their metabolism to the functional activity of the nerve. The kidney 
probably plays an important part in both myoinositol metabolism and excretion. 
                                                                                                                                                   
   
 
Investigators have shown a linear relationship between urea nitrogen retention 
and myoinositol levels. Hypermyoinositolemia has been produced in rats with a 
diet that contains 35% myoinositol; slowed motor nerve conduction velocities 
were induced in sciatic nerve of these animals. Conduction velocities became 
normal after a normal diet was instituted. In brief, myoinositol accumulation in 
progressive uremia, along with accumulation of many other metabolites, may 
correlate with nerve conduction decrement, but its role if any, in precipitating 
neuropathy, remains unclear.6, 9,  10
  
3) Pathologic features: 
Although clinical studies of uremic polyneuropathy have been numerous, 
pathologic studies have been relatively few. Most of these are sural nerve 
biopsy studies. Some confusion regarding the essential morbid anatomy of 
uremic neuropathy appears to have been created by several studies; in which 
demyelinative aspects of the neuropathy were emphasized. The disorder was 
widely assumed to be caused by metabolic dysfunction of the Schwann cells. 
However, in the original clinical and pathological description of this disorder by 
Asbury et al,5 the pathological findings were typical of those that may be seen 
in any neuropathy involving axonal degeneration. Myelin sheaths appeared to 
be affected out of proportion to axons, although a critical judgment about the 
                                                                                                                                                   
   
 
presence of segmental demyelination could not be made because teased nerve 
fiber preparations were not carried properly. Fraser and Arieff 59 postulated that 
neurotoxic compounds deplete energy supplies in the axon by inhibiting nerve 
fiber enzymes required for maintenance of energy production. Although all 
neuronal perikarya would be affected similarly by the toxic assault, the long 
axons would be the first to degenerate since the longer the axon, the greater the 
metabolic load that the perikaryon would bear. In toxic neuropathy, dying back 
of axons is more severe in the distal aspect of the neuron and may result from a 
metabolic failure of the perikaryon. Energy deprivation within the axon may be 
especially critical at nodes of Ranvier, since these nodes demand more energy 
for impulse conduction and axonal transport. 
Nielsen8 theorized that peripheral nerve dysfunction was related to an 
interference with the nerve axon membrane function and inhibition of Na+/K+ -
activated ATPase by toxic factors in uremic serum. Bolton 9 postulated that 
membrane dysfunction was occurring at the perineurium, which functioned as a 
diffusion barrier between interstitial fluid and nerve, or within the endoneurium, 
which acted as a barrier between blood and nerve. As a result, uremic toxins 
may enter the endoneural space at either site and cause direct nerve damage and 
water and electrolyte shifts with expansion or retraction of the space. 
 
                                                                                                                                                   
   
 
  Dyck et al 6 in their study of two patients with uremic peripheral 
neuropathy, concluded that it is a primary axonal degeneration. All fiber sizes, 
both myelinated and unmyelinated are affected, although the largest and the 
most distal fibers are selectively vulnerable. Segmental demyelination occurs in 
the fibers about to undergo breakdown, although nerve fibers degenerating 
rapidly probably bypass the demyelinating phase. Qualitative changes seen on 
electro microscopy include splitting of the myelin lamellae, and their separation 
from the subjacent axolemma and minor mitochondrial abnormalities. No 
consistent abnormalities of neurofilaments or neurotubules are recognized. 
These changes are abnormal, but not distinctive for uremic neuropathy.7 
 
  Semithin transverse section of biopsied sural nerve 
in uremic neuropathy. The nerve shows severe axonal loss of large and small 
fibers. Toluidine blue stain, 200X. 
                                                                                                                                                   
   
 
 Modified trichrome-stained sural nerve in uremic 
neuropathy. The same nerve exhibited marked loss of myelinated fibers. 200X.   
4) Clinical features: 
Uremic neuropathy was described by Asbury and colleagues5 as a distal, 
symmetrical, mixed motor and sensory polyneuropathy that affects legs more 
than arm. There is considerable clinical variation in the severity, tempo of 
progression, presence of dysesthesias and ratio of motor to sensory signs, but 
pattern of distribution (i.e., distal, graded, symmetrical, feet more than arms) 
seems to be inviolate.7 
The restless leg syndrome occurs frequently in uremic patients and 
probably heralds peripheral nerve involvement by the uremic process.10, 59  The 
syndrome consists of creeping, crawling, prickling pruritic sensations deep with 
in the lower limbs, which almost always are worse in the evening and are 
relieved by the movements of the limbs. Nielsen 60 found these symptoms in 
over 40% of 109 patients with varying degrees of renal failure. These symptoms 
were reported by an equal number of patients with and without clinical 
neuropathy (56% and 44% respectively), raising doubts about the significance 
                                                                                                                                                   
   
 
of ‘restless legs’. Whereas some authors (Callaghan as quoted by Asbury5 and 
Thomas61) consider them to be important and early sign of peripheral nerve 
damage.
Muscle cramps of the distal extremities occur commonly in uremic 
patients, many of whom lack evidence of neuropathy. Since cramps often occur 
in acute uremia, they probably represent shifts of fluids into muscle or the 
effects of uremic toxins upon the muscle or the neuromuscular junction.10
‘Burning feet’ identical to those encountered in alcoholic are according to 
Tytler62, a frequent early manifestation of neuropathy, but Neilson60 found that 
only 7 of 109 patients complained of such symptoms, although 40% of his 
patients had some sensory symptoms. Most patients with uremic neuropathy 
have distal dysesthesias, often as an early symptom, described in a variety of 
ways such as painful tingling or electric feelings, unpleasant raw sensations 
resulting from mild cutaneous stimulation of fingers or toes, band like 
constrictive feelings around the feet and ankles or aberrant sensations of 
swelling and turgidity of the fingers or toes or the distal extremities being 
twisted into bizarre positions.7
Impaired vibratory sense in the lower limbs and loss of deep tendon 
reflexes, first ankle jerks and then knee jerks, are the usual first signs of 
peripheral neuropathy.7.10, 60 The rate of progression of the neuropathy varies 
                                                                                                                                                   
   
 
widely among patients, in general it evolves slowly  over several months, 
plateau and then remain stationary despite worsening renal failure.7  
Uremic neuropathy is one type of central-peripheral axonopathies, also 
known as dying-back polyneuropathies, which have been described by Spencer 
and Schaumberg.63   The causes of such central-peripheral axonopathies include 
many types of toxic compounds. These include neuropathies associated with 
diabetes, multiple myeloma, amyloidosis, certain hereditary polyneuropathies, 
and uremia.63 There is also an associated degeneration of the spinal cord, 
particularly involving posterior columns, as well as other portions of the central 
nervous system. Such findings are usually attributed either to local central 
nervous system disease or to damage of spinal ganglion cells secondary to 
ascending peripheral nervous system damage. It is likely, however, that the 
central nervous system components of distal axonopathies. The clinical 
characteristics of such distal axonopathies as described by Schaumberg and 
Spencer include the following 63,64:  
1.    Insidious onset. In most human toxic neuropathies, there is a steady low-
level exposure. Because only the distal portion of selected, scattered 
fibers are affected, the patient may still function well despite the axonal 
degeneration.
                                                                                                                                                   
   
 
2.    Onset in legs. Large and long axons are affected early, and fibers of the 
sciatic nerve are especially vulnerable.
3.    Stocking-glove sensory loss. Degeneration in the distal axon proceeds 
toward the cell body, resulting in clinical signs in the feet and hands 
initially.
4.    Early loss of Achilles reflex. Fibers to the calf muscles are of large 
diameter and among the first affected by many toxins, even when 
longer, smaller-diameter axons in the feet are spared.
5.    Moderate slowing of motor nerve conduction. In demyelinating 
neuropathies, motor nerves or roots are diffusely affected; in axonal 
neuropathies, scattered motor fibers are often intact and motor nerve 
conduction velocity may appear normal or only slightly slow despite 
severe paresis.
6.    Normal cerebrospinal fluid protein content. Pathologic changes are 
usually distal and nerve roots are spared.
7.    Slow recovery. Axonal regeneration (in contrast to remyelination) is 
slow—about 1 mm per day. Thus, after institution of dialysis or renal 
transplantation, recovery of nerve function may take months or years.
                                                                                                                                                   
   
 
8.    Residual disability. Most toxic axonopathies are characterized by tract 
degeneration of long, large-diameter fibers in the central nervous system 
concomitant with changes in the peripheral nervous system. Signs of 
lesions in the corticospinal and spinocerebellar pathways may not be 
clinically apparent if there is severe peripheral neuropathy. However, on 
recovery from the neuropathy, there may be spasticity or ataxia.
 
It can readily be recognized that these features are similar to many 
descriptions of uremic neuropathy. 64, 65  The cellular basis for distal 
axonopathies, however, remains unclear. Spencer and associates 66 have 
emphasized that a number of chemically unrelated neurotoxic compounds and 
several types of metabolic abnormalities can cause strikingly similar patterns of 
distal symmetric polyneuropathy in humans and animals. 
` These authors suggest a possible common metabolic basis for many distal 
axonopathies. Neurotoxic compounds may deplete energy supplies in the axon 
by inhibiting nerve fiber enzymes required for the maintenance of energy 
synthesis. Resupply of enzymes from the neuronal soma may fail to meet the 
increased demand for enzyme replacement in the axon, causing the 
concentration of enzymes to decrease in distal regions. This could lead to a 
local blockade of energy-dependent axonal transport, which could then produce 
                                                                                                                                                   
   
 
a series of pathologic changes culminating distal nerve fiber degeneration. 
Among uremic patients who also have diabetes mellitus, oxidative stress, 
including superoxide accumulation, and accumulation of advanced glycation 
end products (AGEs) appear to be major contributors to the development of 
uremic neuropathy. 8,16 In experimental diabetic neuropathy, there was a 
significant reduction in desert hedgehog mRNA,67 which was substantially 
improved by treatment with sonic hedgehog-IgG fusion protein.67 Such an 
approach may be promising in the management of uremic neuropathy as well. 
In addition to uremic neuropathy, uremic myopathy is a frequent cause of 
weakness, exercise limitation, and rapid onset tiredness in dialysis patients. 68, 69 
Later on, muscle wasting occurs, particularly in the limb muscles 
In general, there are two broad categories of peripheral neuropathy. 
These are described in terms of the pattern of involvement of the peripheral 
nervous system. First, there are processes that result in a bilaterally symmetric 
disturbance of function that can be designated as polyneuropathies. 
Polyneuropathy tends to be associated with agents such as toxic substances, 
metabolic disorders (uremia, diabetes, deficiency states), and certain examples 
of immune reaction that act diffusely on the peripheral nervous system. The 
second category comprises isolated lesions of peripheral nerves 
(mononeuropathy) or multiple isolated lesions (multiple mononeuropathy). In 
                                                                                                                                                   
   
 
severe symmetric polyneuropathies, a generalized loss of peripheral nerve 
function may occur, and the impairment is usually maximal distally in the 
limbs. A mixed motor and sensory polyneuropathy with a distal distribution 
results in weakness and wasting that is most frequently observed peripherally in 
the arms and legs. There are also distal sensory changes of “glove and stocking” 
distribution. In those neuropathies that involve “dying back” of the axons from 
the periphery,64 it is possible that the neurons that have the longest axons to 
maintain appear to be the first to suffer. 
  Clinically, uremic polyneuropathy cannot be distinguished from the 
neuropathies associated with certain other metabolic disorders such as diabetes 
mellitus, chronic alcoholism, and various deficiency states. The occurrence of 
neuropathy bears no relationship to the type of underlying disease process (i.e., 
glomerulonephritis or pyelonephritis). However, certain diseases that can lead 
to renal failure may simultaneously affect peripheral nerve function in a manner 
separate from the manifestations of uremia. Such diseases include amyloidosis, 
multiple myeloma, systemic lupus erythematosus, polyarteritis, nodosa, 
diabetes mellitus, and hepatic failure 5The clinical manifestations of uremic 
neuropathy are characterized by several different stages. It appears that when 
glomerular filtration rate exceeds 12 ml per minute, clinical evidence of 
neuropathy is generally absent. 
                                                                                                                                                   
   
 
Many patients with chronic renal failure who are neurologically 
asymptomatic may exhibit abnormalities on physical examination. They may 
also have evidence of autonomic neuropathy such as impotence and postural 
hypotension. Moreover, in patients who have renal insufficiency, abnormal 
nerve conduction may be present in the absence of symptoms or abnormal 
findings on physical examination. Additionally, alternations in nerve 
conduction do not necessarily indicate structural changes in the peripheral 
nerves. It is often overlooked that many patients with ESRD have autonomic 
dysfunction, which in turn results in impaired baroreceptor sensitivity, which 
can impair blood pressure regulation.70
To summarize, 
• Typical uremic neuropathy symptoms are insidious in onset and consist 
of a tingling and prickling sensation in the lower extremities. 
o Paresthesia is the most common and usually the earliest symptom. 
o Increased pain sensation is a prominent symptom. 
o Weakness of lower extremities and atrophy follow the sensory 
symptoms. As disease progresses, symptoms move proximally and 
involve the upper extremities. 
                                                                                                                                                   
   
 
o Muscle cramps and restless legs syndrome were reported by 67% 
of uremic patients. These symptoms also can be seen in uremic 
patients without neuropathy. 
o Patients report that crawling, prickling, and itching sensations in 
their lower extremities are relieved partially by movement of the 
affected limb. 
• A Guillain-Barré type of presentation is rare, but a rapidly progressive 
course with respiratory failure has been reported. Generalized limb 
weakness develops over days or weeks with imbalance, numbness, and 
diminished reflexes. 
• Mononeuropathies in the form of compressive neuropathy can occur in 
the median nerve at the wrist, in the ulnar nerve at the elbow, or in the 
peroneal nerve at the fibular head. 
o Already partially dysfunctional peripheral nerves may be more 
susceptible to local compression. 
o Connective tissues and tendons are found to have amyloid deposits 
surrounding the carpal tunnel. 
o Multiple distal mononeuropathies present in an extremity 
following the construction of arteriovenous fistulas because of 
distal ischemia. 
                                                                                                                                                   
   
 
Summary of physical examination findings 
• Impaired vibratory perception and absent deep tendon reflexes are the 
most common clinical signs, noted in 93% of patients. 16% had sensory 
loss to pinprick in a glove and stocking distribution. 
• Paradoxical heat sensation was found in the feet of 42% of patients with 
chronic renal failure, as compared to less than 10% of healthy controls. 
• Muscular weakness and wasting were observed in 14%. 
• Cranial nerve involvement is rare; transient nystagmus, miosis, 
impairment of extraocular movement, and facial asymmetry may be 
found rarely on physical examination. 
• Focal weakness, sensory loss, and positive Tinel sign at compression 
sites can be observed in the median, ulnar, or peroneal nerve distribution 
if compressive mononeuropathy is present. 
5)  Effect of Dialysis on peripheral neuropathy: 
 In most patients with end stage renal disease and neuropathy, the 
neuropathy will either stabilize or improve with regular dialysis therapy.10, 
71,72,73,74 In Patients with mild neuropathy dialysis may result in apparent 
recovery. When patients have severe neuropathy before the dialysis is begun, 
recovery may be only partial, even after several years of dialysis.10 The most 
                                                                                                                                                   
   
 
important variable that determines the effects of dialysis on the nerve function 
seems to be the GFR of the patient before onset of dialysis. Peritoneal dialysis 
seems to be associated with lower incidence of peripheral neuropathy.   
6) Intermittent Peritoneal Dialysis: 
It typically involves 12-24 hours of frequent peritoneal dialysis 
exchanges, usually delivered by a cycler in a hospital or in-center setting, two to 
three times weekly. The procedure is not the favored modality because of the 
inadequate clearances due to its intermittent nature, requirement to be in 
hospital and time consuming nature. However, IPD might be the only option for 
elderly dialysis patients with significant co-morbidities, unable to undergo 
haemodialysis (HD) or PD at home without any assistance, for various 
reasons.10 Recent studies prove that IPD is associated with fewer episodes of 
peritonitis, fewer admissions, and longer survival than is often believed.75 
Suitable patients in whom palliative care alone seems inappropriate should not 
be denied a trial of IPD if they choose.76
7) Hemodialysis: 
A great number of patients on long-term haemodialysis have different 
forms of clinically manifested uremic neuropathy (60–75%). Paresthesias is an 
early symptom of uremic neuropathy in patients on haemodialysis. The 
prevalence of these symptoms in different studies varies from 6% to 32% 
                                                                                                                                                   
   
 
Prolonged hemodialytic treatment does not influence the clinical course of 
uremic neuropathy but leads to evident deterioration of electrophysiological 
findings.77-81
 
8) Renal transplantation: 
  Renal transplantation offers the best modality for restoring the peripheral 
nerve functions in patients with ESRD. Most of the studies have proved the 
restoration of clinical and electrophysiological features to near normalcy by the 
normally functioning nephrons in the transplant kidney. Nielson et al 62 
measured sensory and motor nerve conduction in 22 patients after successful 
renal transplantation. In this longitudinal study electrophysiological signs of 
peripheral nerve dysfunction in uremia resolved after successful renal 
transplantation in most patients, in keeping with the remission of clinical 
neurological manifestations. The remission was in two phases; an early, rapid 
phase was followed by a late, slow phase. The recovery was more rapid and 
complete in distal than in proximal segments. The rapid improvement in the 
nerve conduction velocity within weeks demonstrates the superiority of a 
successful renal transplant over hemodialysis in relieving uremic manifestation, 
Bolton et al 82 also emphasized this point. In some series, the disability persists 
in those on long tern dialysis in whom permanent damage has occurred.82,83
                                                                                                                                                   
   
 
 
9) Electrodiagnosis: 
 The most widely used measure of disordered functioning of peripheral 
nerve has been the determination of motor nerve conduction velocities.7 
Preswick in 1964 84 has shown that slowing of nerve conduction is frequent 
occurrence in uremic patients with no other symptoms or signs of neuropathy. 
Jebsen 85 showed that in patients with moderate renal failure not requiring 
dialysis, severe creatinine elevation correlated with decreased velocity of motor 
nerve conduction.  
 Several possible uremic toxins have been identified that appear to be 
correlated with depression of motor nerve conduction velocity (MNCV) in 
laboratory animals. 86, 87 The MNCV has become a standard test for assessment 
of nerve function, although it has many flaws. Most studies do not take into 
account the fact that (1) depressed MNCV is cyclical, with abnormal low values 
one day and normal values the next,88 (2) there is a day-to-day variation in 
MNCV that approaches 20%, and (3) the finding of depressed MNCV in 
laboratory animals associated with high plasma levels of potential uremic 
neurotoxins has generally not been confirmed in human subjects with renal 
failure. 89-92 Although it is possible to relate impairment in MNCV with levels in 
blood of various substances, the best correlation was obtained between reduced 
                                                                                                                                                   
   
 
MNCV versus a reduction in glomerular filtration rate. The motor nerve 
conduction velocity (MNCV) is a test that is frequently used to assess 
peripheral neuropathy. The test, however, is somewhat unreliable because there 
is a large normal variation in MNCV93 and the test has very limited utility in 
detecting moderate impairment of peripheral nerve function. Sensory nerve 
conduction velocity (SNCV) is more sensitive than MNCV, but the test is quite 
painful and most patients do not permit repeated tests. 
Clinical neuropathy appeared generally in patients whose renal function 
deteriorated most markedly and whose conduction velocities slowed the most. 
Neilson19 further pointed out the high degree of correlation between 
diminishing creatinine clearance and reduction of conduction velocities. He also 
demonstrated that the slowing was generalized, motor and sensory, proximal 
and distal, and in arms as well as legs. Later several investigators94 have 
demonstrated that late responses, utilizing the H-reflex and F-wave studies, 
became abnormally slowed early in the course of chronic renal failure at a time 
when standard motor nerve conduction velocities are still normal. The 
electrophysiological deterioration during long term haemodialysis is best seen 
through worsening of the H-wave of tibial and F-waves of peroneal and tibial 
nerves 95,96 
 
                                                                                                                                                   
   
 
                                                                                                                                                   
MATERIAL AND METHODS 
 This study was done in thirty adult patients attending Intermittent 
Peritoneal Dialysis program of the Nephrology Department in Coimbatore 
Medical College and Hospital, Coimbatore.  
Inclusion Criteria :- All patients had advanced stages of chronic kidney 
disease, defined as kidney adamage for 3 months or longer, manifested as 
either pathologic abnormalities or mrkers of kidney damage, including 
abnormalities in composition of blood or urine, abnormality renal imaging 
findings, and a glomerular filtration rate (GFR) of 15-29 ml/min/1.73m2 
(Stage IV) and GFR <15ml/min/1.73m2 (Stage V or End Stage Renal 
Disease).  All patients at the time of evaluation were on intermittent 
peritoneal dialysis, 18-24 hr per sitting, 2-3 times a week. All the patients 
were having intermittent peritoneal dialysis as the sole mode of renal 
replacement therapy.   
Exclusion Criteria :-  Those who had evidence of diabetes, collagen 
vascular disorders, amyloidosis, or any primary neurologic disorder and 
those receiving medications known to affect peripheral nerve function were 
excluded from the study. Alcoholics were also excluded.  
   
 
                                                                                                                                                   
The eligible patients were enrolled for the study by simple random 
sampling, after obtaining informed consent. GFR was estimated by 
calculating creatinine clearance, as per Cockroft-Gault formula.  
Clinical evaluation:-  The history comprised of a through inquiry into all 
symptoms related to peripheral neuromuscular symptoms. The patients were 
requested to give a detailed description of the character and localization of 
sensory symptoms, the time of onset, changes in intensity and their 
significance for their normal activity. The extend of muscular weakness was 
also inquired into. Each patient was subjected to a detailed physical 
examination which included testing of cutaneous sensitivity to (1) light 
touch and pin prick, (2) vibration sense,(3) bulk and tone of muscles, 
strength of muscles (Grading of weakness was done as per Medical Research 
Council Scale) and (5) deep tendon reflexes.  The results were entered in a 
standard proforma. 
Technique of Nerve Conduction Velocity determination: -  a) Motor 
conduction velocity: - In tests on median motor nerve, a surface electrode 
was attached to the skin over the abductor pollicis brevis muscles. A 
reference electrode was attached to the distal phalanx of the thumb and a 
ground electrode placed on the dorsum of the hand. The median nerve was 
supramaximally stimulated first at the wrist and then at the elbow. The 
   
 
                                                                                                                                                   
stimulus artifact and the muscle action potential were displayed on the 
oscilloscope and then recorded. The time latency in milliseconds from 
stimulus at the wrist to onset of muscle response was subtracted from the 
latency after stimulation at the elbow. The lateral popliteal nerve was 
stimulated at the ankle and the knee and the muscle response recorded from 
the extensor digitorum brevis. The posterior tibial nerve was stimulated at 
the ankle and knee, and the muscle response recorded from abductor pollicis. 
. 
 
b) Sensory conduction velocities were determined orthodromically for 
median nerve and antidromically for sural nerve. The digital branches of the 
median nerve was stimulated at the base of the index finger using ring 
electrodes and evoked potentials recorded from the median nerve at the 
wrist, using need electrodes. The sural nerve was stimulated on the posterior 
aspect of the distal third of the leg, at a point slightly lateral to the midline. 
The evoked potentials were recorded using needle electrodes, from below 
the lateral malleolus. 
  
RMS EMG EP MARK-II electromyograph was used for recording the nerve 
conduction velocities. 
   
 
                                                                                                                                                   
Statistical methods: 
Conduction velocities were expressed as standard deviation from the 
arithmetic mean. The student‘t’ test was employed as the test of significance 
when comparing the samples. 
Ten normal healthy controls were drawn from hospital staff and 
relatives of the patients to generate the normal values of the nerve 
conduction studies. 
Peripheral neuropathy was classified into mild, moderate and severe 
according to the following criteria85. 
i) Mild neuropathy: 
Sensory -  absent vibratory sense in feet. 
Motor - Grade 4 strength distally in hands or feet.     
ii) Moderate neuropathy: 
Sensory - absent vibratory sense below knee or decreased    
     pain or touch distally.   
Motor - Grade 3 strength distally. 
iii) Severe neuropathy: 
Sensory - absent pain or touch distally  
Motor - grade 0-1 strength distally. 
 
   
 
                                                                                                                                                   
RESULTS AND ANALYSIS 
Over a period of one and half years thirty patients diagnosed to have 
chronic renal failure were selected for the study, based on the defined criteria.  
The mean duration of uremic symptoms was 19.33 + 12.5 months 
(range 7-52 months). All the patients were undergoing intermittent 
peritoneal dialysis at the time of evaluation, the mean duration after starting 
dialysis being 6.33 + 3.14 months (range 1- 14 months). 
 
Age and sex distribution 
The mean age was 35.6 + 10.6 years (range 18-60 years). There were 19 
males and 11 females. 
Table 1 
AGE DISTRIBUTION 
 
 
 
Age 
(years) 
 
No. of Patients 
 
Percentage of 
total (%) 
     <    20 2 07 
21-30 9 30 
31-40 10 33 
41-50 5 17 
51-60 4 13 
Total 30 100 
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Table 2 
SEX DISTRIBUTION 
 
Sex No. of Patients Percentage 
Male 19 63.33 % 
Female 11 36.67 % 
Total 30 100 % 
 
 
 
Graph 2 
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Table 3 
DISTRIBUTION OF DISEASES 
 
Disease No. of Patients 
Chronic glomerulonephritis 10 
Hypertension 6 
Chronic Interstitial nephritis 3 
ADPKD (misc) 2 
RPGN (misc) 2 
Chronic Pyelonephritis (misc) 1 
Urate Nephropathy (misc) 1 
Unknown 5 
TOTAL 30 
 
Graph 3 
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Table 4 
DISTRIBUTION OF NERVE CONDUCTION VELOCITIES 
 
 
 
Mean Velocity (m/sec) 
Med. Mot Lat. Pop Post. Tib Med. Sen Sural 
 
NCV 
m/sec 
No. NCV No. NCV No. NCV No. NCV No. NCV
 30-34.9    0     _ 5 33.4 
+  
1.29 
8 33.65 
+
1.38 
0 _ 0 _ 
35-39.9 10 38.18 
+ 
1.74 
17 37.54 
+ 
1.46 
12 37.55
+  
1.55 
9 38.48 
+ 
0.99 
20 37.63
+ 
1.46 
40-44.9 12 42.7 
+ 
1.30 
8 41.55 
+  
0.90 
8 41.21
+ 
1.22 
19 41.87 
+ 
1.32 
10 40.88
+ 
0.63 
45-49.9 08 46.96  
   + 
1.10 
0 _ 2 46.45
+ 
0.78 
2 45.5 
+ 
1.14 
0 _ 
Total   30 42.33 
+ 
3.71 
30 37.92 
+
2.96 
30 38.08
+ 
3.85 
30 41.10 
+ 
2.27 
30 38.71
+ 
2.00 
Normal 10 56.10 
+ 
5.40 
10 50.10
+ 
7.2 
 
10 50.2 
+ 
9.3 
10 51.0 
+ 
3.8 
10 52.4 
+ 
4.4 
  
   
 
                                                                                                                                                   
 
 
Table 5 
CONDUCTION VELOCITIES OF NORMAL CONTROLS AND 
UREMIC PATIENTS ON IPD 
 
MEAN VELOCTIY (m/sec) Peripheral 
Nerves Controls Patients 
P Value 
Median Motor 42.33 + 3.71 56.1 + 5.4 < 0.0001 
Lateral Popliteal 37.92 + 2.96 50.1 + 7.2 < 0.0001 
Posterior Tibial 38.08 + 3.85 50.2 + 9.3 < 0.0001 
Median Sensory 41.10 + 2.27 51.0 + 3.8 < 0.0001 
Sural 38.71 + 2.00 52.4 + 4.4 < 0.0001 
 
Graph 4 
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Clinical Neuropathy 
Six patients (20%) complained of burning sensation in the feet. 
Eleven patients (36 %) had clinical neuropathy- mild, as defined earlier 
(Patient Nos. 1, 2, 4, 5, 7, 12, 13, 21, 22, 24, 28, and 30). Four patients (13.3 
%) also had absent ankle jerks bilaterally (Patient Nos. 2, 5, 7 and 13). None 
of the patients had any muscle wasting, weakness, trophic changes or 
sensory ataxia. The duration of uremic symptoms in patients with clinical 
neuropathy was 29 + 13.49 months as against 12.89 + 6.27 months in those 
without clinical neuropathy (P Value < 0.0001).  The duration of IPD in 
patients with clinical neuropathy was 7.5 + 3.8 months and that of those 
without clinical peripheral neuropathy was 5.56 + 2.43 months (P Value = 
Not Significant). 
The mean serum Creatinine in those with clinical peripheral 
neuropathy was 5.03 + 2.60 mg% whereas, that in those without peripheral 
neuropathy was 4.16 + 1.29mg% (P Value = Not Significant) 
 
 
 
   
 
                                                                                                                                                   
 
Table 6 
CONDUCTION VELOCITIES IN PATIENTS WITH AND 
WITHOUT CLINICAL NEUROPATHY 
 
MEAN VELOCTIY (m/sec)  
Peripheral 
Nerves 
Clinical 
Neuropathy 
No Clinical 
Neuropathy 
 
P Value 
Median Motor 41.5 + 3.64 42.88 + 3.76 0.3356 
Lateral Popliteal 36.39 + 2.38 38.95 + 2.93 0.0203 
Posterior Tibial 35.57 + 2.59 39.76 + 3.57 0.0020 
Median Sensory 37.00 + 2.76  41.95 + 2.03 0.0000 
Sural 37.73 + 1.67 39.37 + 1.96 0.0275 
 
 
Table 7 
VARIOUS PARAMETERS IN CLINICAL PERIPHERAL 
NEUROPATHY VS NO CLINICAL PERIPHERAL 
NEUROPATHY 
 
 Clinical 
Neuropathy 
No Clinical 
Neuropathy 
 
P Value 
Duration of Uremic 
symptoms (months) 
29 + 13.49  12.89 + 6.27  0.0001 
Duration of IPD 
(months) 
7.5 + 3.8  5.56 + 2.43  0.0981 
S. Creatinine 
(mg %) 
5.03 + 2.60  4.16 + 1.29  0.2288 
 
 
 
 
 
 
   
 
                                                                                                                                                   
 
Graph 5 
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The mean conduction velocity for posterior tibial nerve in patients 
whose ankle jerks was absent was 34.22 + 3.29 and that of those with 
preserved ankle jerk was 38.67 + 3.63.  (P value < 0.0001). 
 
 
 
 
  
 
 
 
 
 
 
 
 
   
 
                                                                                                                                                   
DISCUSSION 
 Thirty adult patients with end stage renal disease enrolled 
in an Intermittent Peritoneal Dialysis programme for varied indications were 
studied for clinical and electrophysiological evidence of peripheral 
neuropathy. The age and sex distribution of the present group (mean age 35.6 
+ 10.6 years and male to female ratio of 1.72:1) may not reflect the true 
prevalence figure in chronic renal failure, as the patients were exclusively 
drawn from those attending IPD programme in our institution. 
 The mean duration of uremic symptoms in the groups of 
patients studied was 19.33 + 12.50 months. The relatively short duration of 
symptoms could have been an artifact, due to the patient selection criteria. The 
short duration of uremia is probably the reason for the low prevalence of 
clinical neuropathy (36%) in our patients. The mean serum creatinine level 
in our patients at the time of study was only 4.51 + 1.94 mg%, which is a 
reflection of the fact that the patients were on Intermittent Peritoneal Dialysis 
for a mean period of 6.33 + 3.15 months. 
 In a study of 14 patients treated conservatively for end-
stage renal disease, Jebsen et al 97 showed a correlation between increasing 
serum creatinine and decreasing motor nerve conduction velocities. On the 
strength of this study, they defined adequate dialysis as the amount necessary 
   
 
                                                                                                                                                   
to arrest, or prevent the development of peripheral neuropathy 98.In patients 
with chronic renal disease, Blagg et at 99 described slowing of nerve 
conduction with increasing levels of urea and creatinine. Jennekens et al 100 
studied 83 patients with severe renal insufficiency who were being treated 
conservatively for uremia, in order to establish the relationship between 
uremic polyneuropathy and impairment of renal function. They found signs of 
neuropathy only when the creatinine clearance was less than 5 ml/min. 
Polyneuropathy was most frequent in patients with the highest levels of blood 
urea and creatinine, and the lowest creatinine clearances. However the 
duration of severe renal insufficiency also appeared to influence the onset of 
polyneuropathy.  
 In our study clinical evidence of neuropathy was present 
in 36% of our patients, whereas statistically significant slowing of nerve 
conduction velocities was noted in all our patients (Table 5).  With a mean 
creatinine value of 4.51 + 1.94 mg% all our patients (100%) had subclinical 
neuropathy. There were no significant association between the level of serum 
creatinine in those with and those without clinical neuropathy. The association 
between the severity of neuropathy and raising creatinine was also not 
observed. Larger studies are required to delineate the actual association in 
patients on IPD. 
   
 
                                                                                                                                                   
 Six patients (20 %) complained of ‘burning feet’. Tyler 69 
quotes it to be a frequent early manifestation of clinical neuropathy, while 
others 5, 7, 60 found it to be an uncommon symptom. This is probably because, 
although most patients with uremic neuropathy have distal dysesthesias, these 
are not frequently described as ‘burning’ in character, but a variety of 
unpleasant sensations. 
 In our study impaired vibratory sense in the feet was the 
commonest physical sign in the present group of patients, being present in 
9/30 patients (30%). Loss of ankle jerks was seen in 4 patients (13.33%). The 
duration of uremia was significantly longer in patients with clinical 
neuropathy (29 + 13.49 months vs. 12.89 + 6.27 months). The mean serum 
creatinine values were not significantly different in those with and without 
clinical neuropathy, as everybody were receiving intermittent peritoneal 
dialysis. These observations confirm the fact that development of neuropathy 
depends on the duration and severity of renal failure. 6 Impaired vibratory 
senses in the lower limbs and loss of deep tendon reflexes, especially the 
ankle jerks, are the first sign of uremic neuropathy 7, 9, 60 This has been noticed 
in our study also. 
  The course of neuropathy is variable in patients 
undergoing dialysis. Nielson et at101 showed that, on regular haemodialysis, 
   
 
                                                                                                                                                   
there was no further slowing of nerve conduction, nor any significant 
improvement. Many workers have confirmed the lack of improvement in 
neuropathy, on haemodialysis 102,103.  Hemodialysis may reduce serum urea 
and creatinine concentrations without any improvement in neuropathy. The 
absence of improvement in nerve conduction has suggested that impulse 
propagation is impaired by toxic substance(s) of a higher molecular weight, 
and with a considerably lower clearance through the artificial kidney than urea 
and creatinine11. Evidence favoring a toxic role for larger retained solutes 
(500-5000 daltons) is based on two observations: first, anecdotal comparisons 
of patients on chronic haemodialysis and chronic intermittent peritoneal 
dialysis show that patients on the latter mode of therapy may remain well and 
free of uremic neuropathy despite higher BUN and creatinine levels; second, 
lengthening the time on dialysis/week (more "square meter hours" i.e. , 
membrane area multiplied by dialysis time) prevents neuropathy 104, 105. CAPD 
gives relatively high clearances of middle molecules 106-108  
 So it has been hypothesized that peripheral neuropathy 
should not develop on this mode of therapy and, if it already exists, should 
improve. Few studies of nerve conduction velocities have been done in 
patients undergoing CAPD. Lindholm et al 109 reported the appearance of 
neuropathy and deterioration in 11 patients during CAPD, but could not 
   
 
                                                                                                                                                   
exclude the influence of poor nutrition. Pierratos et at 110 found no significant 
change in nerve conduction velocity in 18 patients followed for two years on 
CAPD treatment. 
 The most widely used measure of disordered functions of 
peripheral nerve has been the determination of motor nerve conduction 
velocities. The pathology of uremic neuropathy is focused upon destruction of 
the axon, with only secondary demyelination.6, 7, 10 In this type of neuropathy, 
motor nerve conduction velocity would not be expected to be a guide to the 
severity of the underlying neuropathy.10 also Kominami etal 111 found that 
conduction velocities were unreliable because they varied as much as 9.6 
m/sec from day to day. Sensory nerve conduction velocity probably is more 
sensitive than motor nerve conduction velocity.8,59 Inspite of these drawbacks, 
determination of nerve conduction velocity has been used as objective 
measure of peripheral nerve function by many authors. 60, 84, 85  Slowing of 
nerve conduction is a frequent occurrence in the uremic patients with no other 
symptoms or signs of neuropathy84 which is confirmed in our study also. In 
the present study, we found that all the 112 patients had statistically significant 
slowing of both motor and sensory conduction velocities, while 64% of them 
had no symptoms or signs of peripheral neuropathy. Symptomatic patients had 
   
 
                                                                                                                                                   
significant longer duration of chronic renal failure, when compared to the rest. 
Also, conduction velocities were slower in patients with clinical neuropathy. 
 These findings correlate with the observations of Asbury 7 
, that, in the past decades, the occurrence of clinically evident neuropathy in 
patients on chronic dialysis programme (both haemodialysis and peritoneal 
dialysis) has become rare, as a result of earlier institution of treatment, 
frequent dialysis scheduling and improvement in dialysis techniques.113 In 
contrast, nerve conduction velocity abnormalities, indicative of subclinical 
neuropathy tend to persist unchanged regardless of the type of dialysis 
programme used.101
 Further studies of this nature should try to use conduction 
velocities to assess the adequacy of peritoneal dialysis programme and should 
evaluate the long term prognosis of the patients on peritoneal dialysis based 
on the conduction velocities. Studies have claimed the usefulness of nerve 
conduction studies for prediction of mortality in patients on haemodialysis114. 
Similar studies can be done on peritoneal dialysis patients as well. 
 
  
 
 
   
 
                                                                                                                                                   
CONCLUSIONS 
1) The prevalence of clinical neuropathy in a series of 30 patients with 
end stage chronic kidney disease attending an Intermittent Peritoneal 
Dialysis (IPD) Programme was 36%. Clinical neuropathy occurred in 
those with longer duration of uremic symptoms. 
2) Clinical neuropathy though less observed than sub clinical 
neuropathy, indicative severe axonal damage and worse prognosis. 
3) Slowing of nerve conduction velocities were a universal phenomenon 
in the patients on IPD programme, even in the absence of clinical 
evidence of neuropathy. 
4) Serial electro physiological monitoring may be used to monitor 
adequacy of dialysis schedules. 
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APPENDIX 1 (PROFORMA) 
 
NAME :     AGE:  SEX:  I.P.No: 
 
OCCUPATION:      ADDRESS: 
 
 
Past history: 
 
 
Yes  No 
Diabetes Mellitus   
Thyroid dysfunction   
Joint pains, chronic skin changes   
Photosensitivity    
Medication   
Other systemic illnesses, if any. 
 
  
 
 
General examination: 
 
 
Yes No  
Pallor   
Hyper pigmentation   
Facial puffiness   
Pedal edema   
Thyroid swelling   
Angular stomatitis, cheilosis   
Skin texture   
Others, specify    
 
Pulse:      B.P: 
 
Respiratory rate:    Temperature: 
 
Nutritional status assessment for adequacy of Peritoneal dialysis: 
 
   
 
                                                                                                                                                   
 
 
C.V.S: 
 
 
R.S.: 
 
 
Abdomen: 
 
 
C.N.S.: 
  
Spinomotor system- Bulk, tone and power of the  Upper and Lower limbs. 
 
Deep and superficial reflexes- 
 
Sensory system- Posterior column and spinothalamic tracts. 
 
 
Investigations 
                     
1. Urine complete examination: 
2. 24 hr Urine Protein: 
3. Blood: 
            Hb: gm/dl 
 TC: cells/cu.mm 
 DC:  
 RBC: 
 Peripheral smear: 
   
 
                                                                                                                                                   
4. ESR: 
5. Blood Urea: 6.Serum Creatinine: 
7. Serum Na+: 8. Serum K+: 
9. Calcium:  10.Total protein and albumin 
11.ECG: 
12.USG abdomen: 
 
NERVE CONDUSTION STUDIES: 
1. Sural nerve Sensory Conduction Velocity. 
 
2. Peroneal nerve Maximum Motor Conduction Velocity. 
 
 
 
 
 
 
 
   
 
                                                                                                                                                   
APPENDIX 2 (INFORMED CONSENT) 
DEPARTMENT OF GENERAL MEDICINE , COIMBATORE MEDICAL COLLEGE 
HOSPITAL. 
 
PERIPHERAL NEUROPATHY IN CHRONIC UREMIA – A STUDY OF CLINICAL 
AND ELECTROPHYSIOLOGICAL FEATURES AND CHANGES IN PATIENTS ON 
INTERMITTENT PERITONEAL DIALYSIS. 
Informed consent form for prospective participants 
 
Principal Investigator: Dr Bidhun Kuriakose Paulose, Junior Resident. 
Research Guide:  Prof. Dr S.Veerakesari.MD   Chief, Medical Unit – 
VI. 
Organization:  Department of Medicine, Coimbatore Medical 
College Hospital. 
This informed consent form has two parts 
PART – I  INFORMATION SHEET(to share the information about the 
research with you) 
PART – II CERTIFICATE OF CONSENT (for signatures if you agree to 
take part) 
(You will be given a copy of the full informed consent form.) 
   
 
                                                                                                                                                   
 
PART – I  INFORMATION SHEET 
I , Dr. Bidhun Kuriakose Paulose, Junior resident in Dept of Medicine 
invites you to join as participant in my research on peripheral neuropathy in 
chronic uremia, which is a very common problem in our country. I am going 
to give you information and invite you to be part of this research. You do not 
have to decide today whether or not you will participate in the research. 
Before you decide, you can talk to anyone you feel comfortable with, about 
the research.  
There may be some words that you do not understand. Please ask me to stop 
as we go through the information and I will take time to explain.  If you have 
questions later, you can ask them of me, the study doctor or the staff. 
Chronic Kidney disease is common disease caused by the irreversible 
loss of nephron function which is the functional unit of kidney. This result in 
accumulation of toxic waste materials normally removed by the kidneys, 
resulting in a condition called Uremia, causing a variety of clinical 
manifestations including damage to the peripheral nerves, called peripheral 
neuropathy.  We are doing this research to learn the prevalence of peripheral 
neuropathy in patients with chronic kidney disease who are undergoing 
intermittent peritoneal dialysis which is one of the modalities of treatment of 
   
 
                                                                                                                                                   
Uremia and also to see the correlations with the various clinical and 
biochemical parameters. 
In this study you will have to answer questions regarding your illness, 
undergo a physical examination, give urine, blood for tests, and undergo 
nerve conduction studies. You are being selected because we are inviting all 
adults with chronic kidney disease who is receiving intermittent peritoneal 
dialysis in the nephrology department/medicine department to enroll in the 
study. 
Your participation in this research is entirely voluntary. It is your choice 
whether to participate or not. Whether you choose to participate or not, all 
the services you receive at the department will continue and nothing will 
change. You may change your mind later and stop participating even if you 
agreed earlier. You will have to give details regarding your age, duration of 
disease, family history of the disease, any symptoms you are having at 
present, your past medical problems, and current medications. A doctor will 
examine you to look for any problems. All the data will be recorded in a 
proforma. Ten ml of blood will be drawn for doing various laboratory tests 
to know about the status of your disease. Any excess sample will be 
destroyed immediately after the laboratory tests are completed. Taking the 
blood sample will produce some pain and there may be slight redness at the 
   
 
                                                                                                                                                   
site of puncture for a day or two. Also you will have to provide 3 ml or urine 
for tests. You will be subjected to a nerve conduction study and ultrasound 
scan of your abdomen, all of which cause only minimal discomfort. 
On the first day you will be asked about your problems, a doctor will check 
you up and a proforma will be filled. And necessary blood and urine samples 
will be collected. You will be given a date to return which may be up to a 
week later Ultrasound scan, if not already done. If you participate in this 
research you will be having a thorough check up of your peripheral nervous 
system, This may reveal some unidentified problems in you. We will 
promptly start the treatment for them. Also by participating you are 
providing valuable data that will help doctors understand this disease better 
and ultimately serve the patients in a better way. We will not be providing 
any money for participating in this research; you may incur more expense 
since you will have to visit the hospital more frequently, if situation arise. 
It is possible that if others in the community are aware that you are 
participating in this research, they may ask you questions. We will not be 
sharing the identity of those participating in the research with anyone. The 
information that we collect from this research project will be kept 
confidential. Information about you that will be collected during the research 
will not be identified by your name but by a number. Only the researchers 
   
 
                                                                                                                                                   
will know what your number is and they will lock that information up with a 
lock and key. It will not be shared with or given to anyone except my 
research guide. 
The knowledge that we get from doing this research will be shared with you 
before it is made widely available to the public. Confidential information 
will not be shared. There will be small meetings in the community and these 
will be announced. After these meetings, we will publish the results in order 
that other interested people may learn from our research 
You do not have to take part in this research if you do not wish to do 
so. You may also stop participating in the research at any time you choose. It 
is your choice and all of your rights will still be respected. If you have any 
questions you may ask them now or later, even after the study has started. If 
you wish to ask questions later, you may contact  
Dr Bidhun Kuriakose Paulose,    Prof .Dr.S Veerakesari, 
Junior Resident,     Chief, Medical Unit – VI, 
Dept Of Medicine,     Dept Of Medicine, 
Coimbatore Medical College Hospital  Coimbatore Medical College 
Hospital 
Coimbatore – 18.     Coimbatore- 18. 
Phone – 9788580225.    Phone – 9442589517. 
 
 
   
 
                                                                                                                                                   
This proposal has been reviewed and approved by the Ethics Committee of 
Coimbatore Medical College Hospital which is a committee whose task it is 
to make sure that research participants are protected from harm. 
 CERTIFICATE OF CONSENT 
I have been invited to participate in research on peripheral neuropathy in patients 
with chronic kidney disease. I understand that it will involve answering a detailed 
questionnaire, undergoing a thorough physical exam, giving blood urine samples and 
undergoing nerve conduction studies. I have been informed that the risks are 
minimal and may include only slight pain and redness at sight of needle prick. I am 
aware that there may be no benefit to me personally and that I will not be 
compensated monetarily. I have been provided with the name of a researcher who 
can be easily contacted using the number and address I was given for that person.. I 
have had the opportunity to ask questions about it and any questions I have asked 
have been answered to my satisfaction. I consent voluntarily to participate as a 
participant in this research and understand that I have the right to withdraw from the 
research at anytime without in anyway affecting my medical care. 
Name of the participant:      ____________________ 
Signature of the participant:     ____________________ 
Date:        ____________________ 
         (DD/MM/YY) 
 
 
   
 
                                                                                                                                                   
If illiterate 
A literate witness must sign (if possible , this person should be selected by the 
participant and must have no connection to the research team) 
I have witnessed the accurate reading of the consent form to the potential participant 
, translated to his mother tongue,  and the individual has had opportunity to ask 
questions. I confirm that the individual has given consent freely. 
Name of witness: _________________________ ANDThumb print of 
participant 
Signature of witness: _________________________ 
Date :   _________________________ 
   (Day/Month/Year) 
 
 
I have accurately read or witnessed the accurate reading of the consent form to the 
potential participant, and the individual has had the opportunity to ask questions. I 
confirm that the individual has given consent freely. 
Name of the researcher: ______________________________________ 
Signature of the researcher: ______________________________________ 
Date: (Day/Month/Year)  ____________________________________   
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1 Muthu kum 35 M 52 6 5.1 CGN P A P P P 44.2 31.3 34.3 42 39 55 1.68 1.62
2 Lakshmi 42 F 24 12 2.7 UNKNOWN P A A A P 46.6 33.8 31 43 38 48 1.6 22.2
3 Mylathal 34 F 10 8 3.6 HTN A A P A A 48.1 36.2 33.9 41 35 50 1.49 20.17
4 Fathima 23 F 42 5 4.8 HTN P A A A A 47.6 36.7 35.2 37 35 62 1.58 19.54
5 Selva raj 43 M 24 5 4.1 RPGN P A P P P 43 35.7 33.3 41 35 80 1.84 24.71
6 Pandian 32 M 10 5 6.2 PYE NEPH A A A A A 44.4 42.2 32.3 42 38 64 1.72 15.4
7 James 36 M 52 8 4.3 HTN P A P P P 44 34.8 45.9 43 40 71 1.8 23.24
8 Eswari 35 F 10 4 3.1 RPGN A A P A A 42 33.5 37.2 45.4 39.6 50 1.5 23.05
9 Rajendran 27 M 9 8 5.8 UNKNOWN A A P A A 35 39.6 38 45.6 40.8 72 1.68 6.7
10 Ganesan 27 M 10 5 2.8 CGN A A P A A 40.3 36 35.6 42 38 78 1.88 29.3
11 Tamil selvi 48 F 24 7 5.2 CGN A A P A A 39.8 33.8 36.3 41 36.8 56 1.48 13.67
12 Elangovan 28 M 24 1 11.5 CGN P A A P P 41.6 38.4 38.4 40 39.8 90 1.6 13.16
13 Murugan 43 M 18 10 4.4 CIN P A P A P 39.6 36 34.8 39 37.5 73 1.64 25.65
14 Asiz 18 M 24 6 5.7 ADPKD A A P A A 45.6 41.4 39.6 41.8 40.4 70 1.69 21
15 M.Raja 35 M 9 3 5.9 CGN A A P A A 46.4 38.6 41.6 44.9 41.6 76 1.79 18.5
16 Kuppamma 37 F 12 4 6 UNKNOWN A A P A A 42.5 38.5 40.8 39.4 38.5 63 1.58 13.97
17 Chinnakan 29 M 9 3 4.6 UNKNOWN A A P A A 37.5 36.4 34.8 38.5 36.5 78 1.65 23
18 Moorthy 40 M 9 8 3.6 HTN A A P A A 47.5 42.5 40.6 44.5 40.9 80 1.7 29.9
19 Vasan 26 M 11 6 4.2 CGN A A P A A 48.4 41.5 47 42.5 42 56 1.79 20.4
20 Arulmozhi 54 M 10 10 2.8 URATE A A P A A 43.4 40 40 39.5 38.5 63 1.69 27.5
21 Parthasara 44 M 16 3 1.9 CGN P A P A A 35.2 36.8 34.8 37.5 36.5 59 1.88 28.1
22 Jaffer 26 M 11 8 3.4 CGN P A P P P 38.9 39.6 35.8 38.8 37.6 70 1.66 39
23 Kala 27 F 18 7 3 CIN A A P A A 42.6 40.5 39.8 41.2 40.8 58 1.56 28.6
24 Veeran 54 M 31 11 5.8 ADPKD P A P P P 39.1 38.6 38 37.5 39 60 1.61 13.27
25 Chempaka 28 F 7 2 3.1 HTN A A P A A 43.4 42 40.5 41 40.1 61 1.59 28.3
26 Priya 19 F 14 1 2.2 HTN A A P A A 40.9 39.5 41 42 41.2 48 1.67 29.9
27 Tamarai 50 F 28 8 3.3 CIN A A P A A 38.5 36.5 39 40.5 38.9 57 1.46 21.7
28 Selvi 34 F 33 14 4 CGN P A P A P 39 36 37.7 39.1 36.8 53 1.51 18.6
29 Ayyavu 45 M 8 5 3.9 UNKNOWN A A P A A 45.5 42.3 44 42.2 41 60 1.71 20.2
30 Mahali 51 M 21 7 8.4 CGN A A P A A 39.2 39 41.2 40 38.5 70 1.69 10.5
